Kornimate/medical-research-clean huggingface dataset:
neural mechanisms of change during the treatment of alcohol use disorders with prazosin

Conditions: Alcohol Use Disorder

Summary: the study uses neurobiological measures through brain imaging, neuropsychological measures, and selfreport measures to try to understand how an effective treatment for alcoholism works. on the whole, less than 50% of people with alcoholism get better with treatment. this study will help researchers develop better treatments for alcoholism because if the investigators know why the treatments the investigators use are working, and in whom the treatments work best, then the investigators may be able to make treatment more effective by targeting treatments to individuals who would be most likely to benefit and by guiding development of more effective treatments in the future.


Eligibility criteria:
inclusion criteria: 1. males and females age 18-65 meeting dsm-iv criteria for alcohol dependence in the past year; 2. seeking but not currently receiving treatment; 3. able to provide voluntary informed consent; 4. have at least 4 drinking days in the past 30 days 5. english-speaking 6. have a primary care physician or psychiatrist willing to continue prazosin if the patient tolerates it well and is finding it beneficial. exclusion criteria: 1. severe neurological (e.g., head injury/stroke) conditions, meniere's disease, narcolepsy, benign positional vertigo, heart disease or unstable angina, history of dysrhythmia/syncope, sbp\ 160, dbp\>110, hr\ 110, irregular heart rhythm, chronic renal or hepatic failure, pancreatitis or insulin-dependent diabetes, or other medical problems requiring immediate attention; 2. schizophrenia, schizoaffective disorder, ptsd, bipolar i disorder, suicidal thoughts within the last month; 3. current dependence on another drug of abuse (except nicotine); 4. contraindications to mri (e.g., pacemaker); 5. active legal problems with the potential to result in incarceration; 6. pregnancy or lactation, or child bearing age and not on birth control; 7. currently receiving treatment for alcohol dependence; 8. current use of psychoactive medications including ssri's and other antidepressants, anti-craving medications, anxiolytics including benzodiazepines, antipsychotics, mood stabilizers or anticonvulsants; 9. history of seizures or dt's during alcohol withdrawal.
chinese surgical robot clinical study on rectectomy for rectal cancer

Conditions: Rectal Cancer

Summary: central south university in collaboration with tianjin university developed the first domestically produced chinese minimally invasive surgical (mis) robot system which named "micro hand s" in 2013. this new mis robot had been authorized to enter the clinical trial stage by the ethics committee of the third xiangya hospital at central south university. the micro hand s robot is safe and feasible in the preliminary study. however, compared with minimally invasive approaches (da vici, laparoscope), the merits and demrits of rectectomy for rectal cancer are unclear. therefore, the investigators conduct this retrospective study to focus on this concern.


Eligibility criteria:
inclusion criteria: * histologically confirmed rectal cancer; asa score \< 3 exclusion criteria: * palliative resections, combined resections, distant metastasis, a previous history of abdominal/or pelvic surgery
versartis trial in children to assess long-acting growth hormone

Conditions: Pediatric Growth Hormone Deficiency

Summary: this is a phase 1b/2a study of vrs-317 (long-acting growth hormone) in pediatric patients with growth hormone deficiency. during phase 1b, pediatric patients each will receive a single subcutaneous injection of vrs-317. during the phase 2a stage, patients will receive 6 months of vrs-317 treatment at dose levels selected from the phase 1b stage. the primary endpoints for the study are to determine the safety and efficacy of repeat dose vrs-317.

in phase 1b, separate cohorts of patients will be tested in a single ascending dose format. safety review committee meetings will take place prior to escalating to each increasing dose level. enrolled patients will be monitored for 60 days for safety with pk/pd and safety labs collected. two dose levels will be selected after completion of phase 1b to be tested during phase 2a (6 months of continuous vrs-317 treatment). safety and pk assessments will be made during the phase 2a stage. patient heights will be measured by stadiometer.

Eligibility criteria:
inclusion criteria: * chronological age ≥ 3.0 years and ≤ 11.0 * diagnosis of ghd as documented by gh stimulation test * below average height sds at screening * appropriate weight for stature * decreased igf-i sds at screening * delayed bone age * normal thyroid function test results at screening visit * legally authorized representative informed consent. exclusion criteria: * prior treatment with any growth promoting agent * documented history of, or current, significant disease * chromosomal aneuploidy, significant gene mutations * diagnosis of attention deficit hyperactivity disorder * daily use of anti-inflammatory doses of glucocorticoid * prior history of leukemia, lymphoma, sarcoma or cancer * known allergy to constituents of the study drug formulation * abnormal ocular findings at screening * significant abnormality in screening laboratory studies

Keywords: growth hormone growth hormone deficiency growth pediatric growth hormone deficiency long acting growth hormone ghd pghd vrs 317 exten versartis
imgts for patients with cerebral palsy and with mobility limitations (phase 2)

Conditions: Cerebral Palsy

Summary: the proposed research project aims to answer the question "are immersive technology systems effective in the rehabilitation management of pediatric patients with cerebral palsy and with mobility limitations?". the current study is the second of three phases, and it aims to create an immersive gamification technology system for the management of patients with cerebral palsy and with mobility disorders and to determine its clinical effectiveness, safety, and usability among children with mild to moderate cerebral palsy.


Eligibility criteria:
inclusion criteria: * aged 6-12 years old * able to walk without a mobility device with limited speed, balance, and/or coordination (equivalent to gross motor function classification system - expanded and revised (gmfcs) level i or ii) * can handle objects easily and successfully (equivalent to manual ability classification system, macs, level i) * able to follow one-step instructions during botmp exclusion criteria: * children with cp functioning at gmfcs level iii or higher * children who are totally dependent (i.e., those who require 100% assistance or support from another adult to complete tasks or for transfers or ambulation) * have had episodes of seizures or previously diagnosed as having epilepsy or are taking antiepileptic or seizure medications * have significant visual impairment * have hearing impairment requiring hearing aid * have a history of motion sickness * experience claustrophobia
study of pasireotide in patients with rare tumors of neuroendocrine origin

Conditions: Pancreatic Neoplasm; Pituitary Neoplasm; Nelson Syndrome; Ectopic ACTH Syndrome

Summary: this study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.


Eligibility criteria:
inclusion criteria: * male and female patients at least 18 years old * patient who have rare tumors of neuroendocrine origin, such as tumors of the: 1. pancreas 2. pituitary glands 3. nelson syndrome 4. ectopic-acth secreting tumor * patients who have failed standard of care treatment or for whom no standard of care treatment exist * signed informed consent exclusion criteria: * patients with active gallbladder disease * patients with any ongoing or planned anti-neoplastic or interferon therapy * poorly controlled diabetes mellitus * female patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control other protocol-defined inclusion/exclusion criteria may apply.

Keywords: rare tumors of neuroendocrine origin nets of the pancreatic pituitary nets eas tumors nelson's syndrome pancreatic neoplasm pituitary neoplasm nelson syndrome ectopic acth syndrome pasireotide lar pnets pinets
centralized pan-russian survey of the undertreatment of hypercholesterolemia ii (cepheus ii)

Conditions: Dyslipidaemia

Summary: this is a multi-center survey of patients who are currently receiving lipid-lowering medications and have a moderate or higher cardiovascular (cv) risk. the survey will be conducted in the russian federation. data collection for each study subject will be done within one physician visit. if an enrolled subject comes to the visit not fasting (for at least 8 hours), an appointment for the blood tests will be made for another day.

this is a multi-center survey of patients who are currently receiving lipid-lowering medications and have a moderate or higher cv risk. the survey will be conducted in the russian federation. data collection for each study subject will be done within one physician visit. if an enrolled subject comes to the visit not fasting (for at least 8 hours), an appointment for the blood tests will be made for another day. prior to the assessment of the first subject at a site, each investigator will complete an investigator questionnaire on his/her experience and perception of the management of hypercholesterolemia in his/her patients. prior to the assessment, subjects will record on a patient questionnaire their awareness of hypercholesterolemia, their current treatment schedule, their perception, and compliance. the investigator will complete a case report form (crf) with the subject's demographics, known cardiovascular risk factors, cardiovascular medical history, current lipid-lowering drug therapy, and the reason for this therapy. fasting blood samples will be taken in tubes to test for total cholesterol, low-density lipoprotein cholesterol (ldl), high-density lipoprotein cholesterol (hdl), glucose, creatinine, hemoglobin a1c, hemoglobin, and hematocrit at a central laboratory in the russian federation.

Eligibility criteria:
inclusion criteria: * properly obtained written informed consent from the potential subject. * on lipid-lowering drug therapy for at least 3 months (90 days), with no dose change for a minimum of 8 weeks (56 days). * scheduled blood tests for total cholesterol (tc), hdl-c, ldl-c, glucose, creatinine, hba1c, hb, and hematocrit on the visit when they are considered for survey participation, or these tests must be decided to be necessary for study-unrelated purposes during that visit. exclusion criteria: * subjects who are unwilling or unable to provide written informed consent. * the cognitive status of a potential subject and/or their home environment (in the investigator's opinion) might compromise the compliance with the treatment regimen during the past 8 weeks. * a low cv risk. * participating in any other clinical trial.

Keywords: dyslipidaemia ldl-c goals guidelines
retro-auricular single-site endoscopic to papillary thyroid carcinoma

Conditions: Papillary Thyroid Carcinoma

Summary: the goal of this non randomized control clinical research study is to compare the cosmetic outcomes and efficiacy of retro-auricular single-site endoscopic thyroid lobectomy and central lymph node dissection against conventional resection.


Eligibility criteria:
inclusion criteria: 1. age 18-70 years old, no gender restrictions. 2. fine-needle aspiration cytology(fna) confirmed papillary thyroid carcinoma(ptc). 3. early stage ptc (stage t1n0m0). 4. preoperative ultrasonography showed unilateral glandular lobe malignant tumor and the largest diameter was not more than 2cm, without cervical lymph node metastasis and extensive metastasis. 5. patients undergoing thyroid lobectomy and central lymph node dissection. 6. patients who have signed an approved informed consent. exclusion criteria: 1. patients who do not accept case data collection for various reasons. 2. the clinical data unfit this study (at the discretion of the investigator). 3. patients who have undergone neck surgery or radiotherapy before this trail. 4. patients who have uncontrolled hyperthyroidism.

Keywords: papillary thyroid carcinoma thyroidectomy laparoscopy retroauricular approach single-site
comparing the effectiveness of a treat-to-target (t2t) disease management strategy vs. routine care (rc) in adult patients with moderate to severe rheumatoid arthritis (ra) treated with subcutaneous abatacept (orencia - sc)

Conditions: Rheumatoid Arthritis

Summary: this is a 12 month prospective, multicenter, post-marketing, observational study to compare the effectiveness of a treat-to-target (t2t) disease management strategy vs. routine care (rc) in adult patients with moderate to severe rheumatoid arthritis (ra) treated with subcutaneous abatacept (orencia - sc). patients completing the study will be offered to participate in a 12-month extension of their follow-up provided that this is in agreement with the judgment of the treating physician.


Eligibility criteria:
inclusion criteria: * 18 years of age or older. * active moderate to severe ra, defined as cdai \> 10. * the treating physician has made the decision to initiate treatment with sc abatacept in accordance with the canadian product monograph. * patient has provided a written informed consent and is able to complete the survey requirements. * patient fulfills the reimbursement criteria for treatment with sc abatacept under provincial or private health insurance reimbursement coverage. exclusion criteria: * has received abatacept (sc or iv) prior to the enrolment visit. * has failed more than one prior biologic dmard therapy * has a history of autoimmune disease or of any joint inflammatory disease other than ra with the exception of concomitant secondary sjogren's syndrome. * is participating in an ongoing clinical trial and/or has received treatment with an investigational agent within 4 weeks before starting treatment with sc abatacept. * is participating in another industry-sponsored observational study. * patients participating to non-industry related registries or other data collection studies can be included * presence of any condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of ra treatment.
efficacy, safety and pharmacokinetics of tinzaparin during slow low efficient daily dialysis in intensive care patients

Conditions: Acute Kidney Injury; Renal Replacement Therapy; Anticoagulants

Summary: this study evaluates the pharmacokinetics of tinzaparin during renal replacement therapy (rrt). 60 patients with clinical indication for pharmacological thromboprophylaxis and slow low efficient daily dialysis (sledd) will be studied in tampere university hospital. all subjects will receive a 4500 iu bolus of tinzaparin. the subjects in study group (n=30) will also receive a 4500 iu continuous infusion of tinzaparin.

after written informed consent, 60 subjects with clinical indication for pharmacological thromboprophylaxis and sledd will be studied in the tampere university hospital intensive care unit. after inclusion the subjects will be randomly assigned into study group (30 patients) and control (30 patients). all subjects receive a bolus of tinzaparin 4500 iu into the inlet line of dialyzer at 5 minutes after the start of blood pump. afterwards the subjects in the study group will continue to receive continuous tinzaparin infusion (concentration 100 iu/ml) 500 iu/h over seven hours. no other heparin product (including arteria flush lines) nor dilution fluids at the dialyzer are allowed during the study period of 24 hours. each sledd treatment will be performed with cordiax 5008s (fresenius) for 8 hours. after the study period of 24 hours thromboprophylaxis will be prescribed according to the normal practice in the icu. the primary outcome measure is plasma anti-fxa concentration at 4 hours from the onset of sledd. plasma anti-fxa will be drawn at timepoints 0 hours, 4 hours, 8 hours and 24 hours from the onset of the dialysis. the clotting formation in rrt system will be evaluated by clotting scoring. in the case of serious clotting rrt treatment is stopped and the new rrt is started. the study will end to the new rrt.

Eligibility criteria:
inclusion criteria: * critically ill patients requiring intensive care * indication for pharmacological thromboprophylaxis * written informed consent obtained from the patient or his/her legal representative * indication for sledd, any of following: * serum creatinine concentration of more than 354 micromol/l or greater than 3 times the baseline creatinine level or * anuria (urine output of 100 ml/day) for more than 12 hours or * oliguria: below 0.3 ml/kg/h for more than 24 hours or 500 ml/day * the presence of clinically significant organ edema (e.g., pulmonary edema, elevated intra-abdominal pressure, significant peripheral swelling) together with oliguria or anuria * dialysis dependence after continuous renal replacement treatment exclusion criteria: * other indications for anticoagulant therapy than thromboprophylaxis (including sodium citrate for crrt) * any long-term anticoagulant or antithrombotic medication, except for low-dose aspirin (\<150 mg daily) * treatment with tinzaparin or any other lmwh or heparin within 24 hours of study inclusion * known heparin induced thrombocytopenia (hit), or hypersensitivity to tinzaparin or any other heparin * known pregnancy
pudendal nerve fluoroscopic guided pulsed radiofrequency for treatment of superficial dyspareunia

Conditions: Superficial Dyspareunia

Summary: superficial dyspareunia represents a major health problem especially for the newly wed couples. pulsed radiofrequency for pudendal nerve is a non-neurolytic neuromodulatory method that is effective in relief of this type of pain. objectives: to evaluate the efficacy of bilateral pudendal nerve fluoroscopic guided pulsed radiofrequency in treatment of intractable non-organic dyspareunia, and compare between trans-gluteal and transvaginal approaches regarding patient comfort and satisfaction.


Eligibility criteria:
inclusion criteria: * women aged between 16 and 46 years and from a near vicinity to our facility to make her available for follow-up exclusion criteria: * we had excluded women with any abnormality in the transvaginal us guided imagining, or those with any evidence of local gynecological abnormalities on examination. meanwhile, we had excluded those women with infection at site of injection, coagulopathy or other bleeding diathesis, pre-existing neurologic deficit in the targeted region, those with history of chronic opioid use and women who refused to participate in the study
delayed cord clamping at term cesarean

Conditions: Maternal Blood Loss; Cesarean Delivery; Delayed Cord Clamping; Neonatal Health

Summary: the purpose of this research study is to find out how delaying cutting the umbilical cord until one minute after delivery of the baby during a cesarean impacts the amount of blood the mother loses during surgery. the study will also examine the benefits to the newborn from delayed cord clamping during cesarean.

after delivery of a baby, the umbilical cord is cut to separate the baby from the placenta and the mother. the best time to cut the umbilical cord of full term babies is unknown. traditionally, the umbilical cord is cut immediately at birth. there is however, continued blood flow from the placenta to the baby after delivery and so there may be a benefit to the baby from waiting to cut the cord until one minute after delivery. studies show that delaying cutting the cord until at least one minute after delivery increases a full term baby's blood count in first two days of life and increases the baby's iron levels. the impact of delaying cutting the umbilical cord on a mother's health is not fully known. delaying cutting the cord has minimal impact on the mother's health when the baby is delivered vaginally, but it is not known how delaying cutting the cord impacts the mother's health (and specifically the amount of blood a mother loses at delivery) when the baby is delivered by cesarean.

Eligibility criteria:
inclusion criteria: * singleton gestation * scheduled cesarean delivery at term (\>=37 weeks) exclusion criteria: * placenta previa * placenta abruption * intrauterine growth restriction with abnormal dopplers * fetal anomalies * known fetal anemia * planned cord blood banking * preeclampsia * significant maternal anemia (hgb \<=7)

Keywords: maternal blood loss cesarean delivery delayed cord clamping neonatal health
effect of gh administration in poor responders undergoing intracytoplasmic sperm injection (icsi)

Conditions: Female Infertility

Summary: despite the use of various treatment strategies, poor response to ovarian stimulation remains a major clinical challenge with lower chance to obtain sufficient number of oocytes and thus less likely to conceive with high risk of cycle cancellation. the aim of this study is to evaluate the effect of recombinant human gh administration to gonadotropins on clinical and laboratory icsi outcomes in expected poor responders more and less than 35 years (poseidon group 4 and 3 respectively).


Eligibility criteria:
inclusion criteria: 1. infertile women aged 20-45 years. 2. afc \<5. 3. amh level \<1.2 ng/ml. 4. have two normal ovaries and normal uterine cavity. exclusion criteria: 1. body mass index (bmi) \>30 kg/m2. 2. follicle stimulating hormone (fsh) \> 15 iu/l. 3. history of abnormal karyotype in one or both partners. 4. endocrine, metabolic or autoimmune disorders, such as diabetes, thyroid disorder, and polycystic ovary syndrome (pcos). 5. women with a known medical disease (e.g. severe hypertension or hepatic disease). 6. endometriosis. 7. previous ovarian surgery. 8. current or history of malignancies, chemotherapy or radiotherapy. 9. severe male actor (total motile sperm count \<1×106 or normal morphology \<1%)

Keywords: growth hormone poor responder poseidon group, icsi